HighTide integrates expertise in disease biology, medicinal chemistry, clinical development and regulatory affairs to advance its growing pipeline of drugs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity. HighTide’s continued clinical progress with HTD1801 includes an ongoing Phase 2 study for the treatment of type 2 diabetes (T2DM), the initiation of a global Phase 2b study for the treatment of nonalcoholic steatohepatitis (NASH), and the successful end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) for primary sclerosing cholangitis (PSC). The U.S. FDA has granted HTD1801 Fast Track designation in both NASH and PSC.
New molecular entity: ionic salt of two active moieties
Peptide analog of RegIII/PAP protein active fragment
An innovative fixed dose combination of two known compounds with clear differentiation for unmet clinical needs
© 2020 HighTide Therapeutics Inc.